EuroPCR 2018 | Meta-Analyzis on Cerebral Protection Devices during TAVR

The risk of stroke is inherent to TAVR and, apart from clinically manifest events, there is abundant evidence of cerebral embolic lesions during TAVR provided by studies using diffusion weighted MRI or transcranial doppler ultrasound. Several devices have been developed to reduce the risk of stroke, though they have been assessed by relatively small trials with controversial outcomes. The aim of this study was to gather all available evidence and carry out a meta-analyzis on the safety and efficacy of embolic protection devices during TAVR.

TAVI-proteccion-cerebral2This meta-analyzis inc luded 8 studies with a total 1285 patients. Success rate of embolic protection devices was 94.5%.

 

Global incidence of stroke was 4.8% in patients using embolic protection devices and 6% in patients with no protection. Silent new ischemic lesions rate detected by diffusion MRI was 80%.

 

The use of protection devices was not associated to differences in mortality at 30 days (OR: 0.43, CI 95% 0.18 to 1.05; p=0.3) but it was associated to a lower rate of stroke in the same period (OR: 0.45, CI 95% 0.31 to 0.98; p=0.04), with a number needed to treat of 33 patients to prevent a new event.


Read also: EuroPCR 2018 | SYNTAX III REVOLUTION: Excellent Correlation Between Angiography and Computerized Tomography in Patients with Left Main and Multivessel Disease.


There were no differences in number of new lesions, but the new devices were associated to a lower total volume of lesions. The greatest benefit of embolic protection devices was observed in self-expandable valves.

 

Conclusion

The use of embolic protection devices was not associated to a reduction in mortality during TAVR but to a lower rate of stroke at 30 days. There was no reduction in new lesions diagnosed by diffusion MRI, but there was a reduction in lesion volume.

 

Título original: Cerebral protection during TAVR reduces the incidence of major cerebrovascular events: results from an up-to-date systematic review and meta-analysis.

Presentador: L. Testa.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

Experience with the intra-annular self-expanding Navitor valve: data from the STS/ACC TVT registry

The expansion of TAVI, with the introduction of new-generation devices, has prioritized not only periprocedural safety, but also the preservation of coronary access, more...

The Two Sides of the Coin: What Do CHAMPION-AF and CLOSURE-AF Teach Us About Left Atrial Appendage Closure?

Letter to the editor: Juan Manuel Pérez Asorey Percutaneous left atrial appendage closure (LAAO) is currently going through one of the most interesting stages of...

CLOSURE-AF: Percutaneous Left Atrial Appendage Closure versus Medical Therapy in Atrial Fibrillation

Percutaneous left atrial appendage closure has been proposed as an alternative to anticoagulation in patients with atrial fibrillation and high bleeding risk; however, comparative...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

High Ischaemic Risk Criteria in Chronic Coronary Syndrome: Prevalence and Prognosis

Despite advances in the management of chronic coronary syndrome (CCS), including the widespread use of drug-eluting stents (DES) and the optimization of medical therapy,...

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

Experience with the intra-annular self-expanding Navitor valve: data from the STS/ACC TVT registry

The expansion of TAVI, with the introduction of new-generation devices, has prioritized not only periprocedural safety, but also the preservation of coronary access, more...